Insulet Corp. said Horizon, its artificial pancreas, could be on the U.S. market in late 2019. Horizon is the Billerica, Mass.-based firm's first foray into continuous glucose monitoring-automated insulin delivery. If Insulet's Horizon gains FDA approval, it would go up against Dublin-based, Medtronic plc's Minimed 670G artificial pancreas, which received FDA approval in September and is set to launch in April of next year. (See Medical Device Daily, Sept. 29, 2016.) Read More
